triiodothyronine (T3)

DRUG2 trials

Sponsors

Hadassah Medical Organization, Aultman Health Foundation

Conditions

Major Depressive DisorderMetastatic Breast CancerThyroid Dysfunction

Phase 2

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

TerminatedNCT03787303

Aultman Health FoundationMetastatic Breast Cancer, Thyroid Dysfunction

Start: 2019-03-01End: 2022-03-09Updated: 2022-05-13

Unknown Phase

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

CompletedNCT00421369

Hadassah Medical OrganizationMajor Depressive Disorder

Start: 2007-09-30End: 2011-08-31Updated: 2013-03-22

Related Papers

B-TREUH results: A single-arm phase II pilot study of euthyroid hypothyroxinemia in metastatic breast carcinoma.

Journal of Clinical Oncology2023-06-01

B-TREUH: A single-arm phase II pilot study of euthyroid hypothyroxinemia in metastatic breast carcinoma.

Journal of Clinical Oncology2020-05-20